QIAGEN's GeneReader NGS System Delivers Accuracy and Ease of Use for Clinical Research in Oncology
HILDEN, Germany and GERMANTOWN, Maryland, November 14, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt Prime Standard: QIA) today announced new studies highlighting the outstanding analytical performance and ease of use of the GeneReader NGS System, the world's first complete Sample to Insight solution for next-generation sequencing. The studies are being presented this week at the Association for Molecular Pathology (AMP) 2017 Annual Meeting in Salt Lake City, Utah, where QIAGEN also will demonstrate the GeneReader and other Sample to Insight solutions.
Theradaptive, the market leader in targeted regenerative therapeutics, today announced the expansion of its senior leadership team with the appointment of Dr. Frank Vizesi, Ph.D. as Chief Scientific Officer....
Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today positive changes to commercial payer policies covering patients who could benefit from the iTindtm procedure, a minimally...
"I wanted to create a protective covering that can be used with any public seating," said an inventor, from Cerritos, Calif., "so I invented the TRANSIT SEAT PAD. My design eliminates the need to wipe seats or find a cleaner seat to use."...
The global influenza vaccine market size is estimated to grow by USD 2933.88 mn from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of 6.89% during the forecast period. The global influenza vaccine market is...
National survey of women ages 25+ finds strong bipartisan support for improving Medicare to cover home care and treatment for chronic diseases
View in browser
Key takeaways
Half of women say they feel "uncertain" or "worried" when they think about...
Registration is now open for Wayfinder Family Services' Camp Bloomfield, which is free of charge for children and teens who are blind or visually impaired....
